CXCL11 and neoplasm: However, in a non-immunogenic tumor model, treatment with vvDD-CXCL11 monotherapy was not effective, necessitating its combination with a drug cocktail chosen for its ability to (re)condition the TME, which led to improved therapeutic efficacy in the MC38 colon tumor model (74).